All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 164.34 points (-0.9%) at 17,347 as of Wednesday, Aug. 19, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 562 issues advancing vs. 2,422 declining with 143 unchanged.

The Drugs industry as a whole closed the day down 0.5% versus the S&P 500, which was down 0.9%. Top gainers within the Drugs industry included Skystar Bio-Pharmaceutical ( SKBI), up 2.0%, Jaguar Animal Health ( JAGX), up 3.4%, Innocoll ( INNL), up 3.8%, Celsus Therapeutics ( CLTX), up 287.8% and Merus Labs International ( MSLI), up 3.9%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Merus Labs International ( MSLI) is one of the companies that pushed the Drugs industry higher today. Merus Labs International was up $0.07 (3.9%) to $1.85 on light volume. Throughout the day, 6,058 shares of Merus Labs International exchanged hands as compared to its average daily volume of 41,500 shares. The stock ranged in a price between $1.79-$1.87 after having opened the day at $1.82 as compared to the previous trading day's close of $1.78.

Merus Labs International Inc., a specialty pharmaceutical company, engages in the acquisition and licensing of prescription medicines in the United States, Canada, and Europe. Merus Labs International has a market cap of $184.2 million and is part of the health care sector. Shares are up 7.7% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst who rates Merus Labs International a buy, no analysts rate it a sell, and none rate it a hold.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreet Ratings rates Merus Labs International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and compelling growth in net income. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year.

Highlights from TheStreet Ratings analysis on MSLI go as follows:

  • MSLI's very impressive revenue growth greatly exceeded the industry average of 6.8%. Since the same quarter one year prior, revenues leaped by 89.5%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • The debt-to-equity ratio is somewhat low, currently at 0.63, and is less than that of the industry average, implying that there has been a relatively successful effort in the management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.19, which illustrates the ability to avoid short-term cash problems.
  • MERUS LABS INTERNATIONAL INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past 2 years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, MERUS LABS INTERNATIONAL INC reported poor results of -$0.16 versus -$0.05 in the prior year.
  • The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Pharmaceuticals industry and the overall market, MERUS LABS INTERNATIONAL INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • In its most recent trading session, MSLI has closed at a price level that was not very different from its closing price of one year earlier. This is probably due to its weak earnings growth as well as other mixed factors. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.

You can view the full analysis from the report here: Merus Labs International Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

At the close, Innocoll ( INNL) was up $0.49 (3.8%) to $13.50 on average volume. Throughout the day, 4,995 shares of Innocoll exchanged hands as compared to its average daily volume of 4,500 shares. The stock ranged in a price between $12.48-$13.70 after having opened the day at $12.85 as compared to the previous trading day's close of $13.01.

Innocoll has a market cap of $260.1 million and is part of the health care sector. Shares are up 119.2% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Skystar Bio-Pharmaceutical ( SKBI) was another company that pushed the Drugs industry higher today. Skystar Bio-Pharmaceutical was up $0.03 (2.0%) to $1.46 on light volume. Throughout the day, 880 shares of Skystar Bio-Pharmaceutical exchanged hands as compared to its average daily volume of 21,100 shares. The stock ranged in a price between $1.45-$1.46 after having opened the day at $1.45 as compared to the previous trading day's close of $1.43.

Skystar Bio-Pharmaceutical Company researches, develops, produces, markets, and sells veterinary healthcare and medical care products in the People's Republic of China. Skystar Bio-Pharmaceutical has a market cap of $12.5 million and is part of the health care sector. Shares are down 66.1% year-to-date as of the close of trading on Tuesday. Currently there are no analysts who rate Skystar Bio-Pharmaceutical a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Skystar Bio-Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and compelling growth in net income. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year.

Highlights from TheStreet Ratings analysis on SKBI go as follows:

  • The revenue growth came in higher than the industry average of 6.8%. Since the same quarter one year prior, revenues rose by 14.8%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • SKBI's debt-to-equity ratio is very low at 0.16 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.20, which illustrates the ability to avoid short-term cash problems.
  • The gross profit margin for SKYSTAR BIO-PHARMACEUTICAL is rather high; currently it is at 50.16%. Regardless of SKBI's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, SKBI's net profit margin of 26.75% significantly outperformed against the industry.
  • The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. When compared to other companies in the Pharmaceuticals industry and the overall market, SKYSTAR BIO-PHARMACEUTICAL's return on equity is below that of both the industry average and the S&P 500.
  • SKBI's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 72.98%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.

You can view the full analysis from the report here: Skystar Bio-Pharmaceutical Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.